{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:57:11Z","timestamp":1793051831013,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cutaneous leishmaniasis (CL) is a neglected tropical disease causing an estimated 1 million new cases annually. While antimonial compounds are the standard of care worldwide, they are associated with significant adverse effects. Miltefosine, an oral medication, is United States (US) Food and Drug Administration approved to treat CL caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis. Evidence of efficacy in other species and side-effect profiles in CL has been limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-six patients with CL were treated with miltefosine at the US National Institutes of Health. Species included L. braziliensis (n = 7), L. panamensis (n = 5), Leishmania mexicana (n = 1), Leishmania infantum (n = 3), Leishmania aethiopica (n = 4), Leishmania tropica (n = 2), Leishmania major (n = 1), and unspeciated (n = 3). Demographic and clinic characteristics of the participants, response to treatment, and associated adverse events were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment with miltefosine resulted in cure in 77 % (20\/26) of cases, with cures among all species. Common adverse events included nausea\/vomiting (97%) and lack of appetite (54%). Clinical management or dose reduction was required in a third of cases. Gout occurred in 3 individuals with a prior history of gout. Most laboratory abnormalities, including elevated creatinine and aminotransferases, were mild and normalized after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that miltefosine has good but imperfect efficacy to a wide variety of Leishmania species. While side effects were common and mostly mild to moderate, some resulted in discontinuation of therapy. Due to oral administration, broad efficacy, and manageable toxicities, miltefosine is a viable alternative treatment option for CL, though cost and lack of local availability may limit its widespread use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1238","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T15:29:39Z","timestamp":1602602979000},"page":"e2457-e2562","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis"],"prefix":"10.1093","volume":"73","author":[{"given":"JeanAnne M","family":"Ware","sequence":"first","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brown","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wetzler","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawsar R","family":"Talaat","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B","family":"Nutman","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore E","family":"Nash","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"2021100522225270300_CIT0001","article-title":"World Health Organization. Leishmaniasis"},{"key":"2021100522225270300_CIT0002","article-title":"Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis","volume":"26:taz055","author":"Boggild","year":"2019","journal-title":"J Travel Med"},{"key":"2021100522225270300_CIT0003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.idc.2018.10.004","article-title":"Cutaneous leishmaniasis: updates in diagnosis and management","volume":"33","author":"Aronson","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"2021100522225270300_CIT0004","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021100522225270300_CIT0005","volume-title":"Miltefosine package insert","author":"US Food and Drug Administration","year":"2014"},{"key":"2021100522225270300_CIT0006","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/429238","article-title":"Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru","volume":"40","author":"Miranda-Ver\u00e1stegui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021100522225270300_CIT0007","article-title":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5 Published November 27 2017"},{"key":"2021100522225270300_CIT0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4269\/ajtmh.2011.10-0437","article-title":"A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis","volume":"84","author":"Ramanathan","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2021100522225270300_CIT0009","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cid\/ciy619","article-title":"Topical 15% paromomycin-aquaphilic for bolivian leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial","volume":"68","author":"Soto","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021100522225270300_CIT0010","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1086\/322689","article-title":"Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent","volume":"33","author":"Soto","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2021100522225270300_CIT0011","doi-asserted-by":"crossref","first-page":"e0006986","DOI":"10.1371\/journal.pntd.0006986","article-title":"Interventions to treat cutaneous leishmaniasis in children: a systematic review","volume":"12","author":"Uribe-Restrepo","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2021100522225270300_CIT0012","doi-asserted-by":"crossref","first-page":"e0005515","DOI":"10.1371\/journal.pntd.0005515","article-title":"Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: a cohort study","volume":"11","author":"Castro","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2021100522225270300_CIT0013","first-page":"1530","article-title":"Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase II clinical trial","volume":"68","author":"Mbui","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021100522225270300_CIT0014","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021100522225270300_CIT0015","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2021100522225270300_CIT0016","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"2021100522225270300_CIT0017","first-page":"CD005067","article-title":"Interventions for Old World cutaneous leishmaniasis","volume":"12","author":"Heras-Mosteiro","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2021100522225270300_CIT0018","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1155\/2008\/802710","article-title":"Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan","volume":"19","author":"Keynan","year":"2008","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2021100522225270300_CIT0019","doi-asserted-by":"crossref","first-page":"e0004495","DOI":"10.1371\/journal.pntd.0004495","article-title":"Treatment of cutaneous leishmaniasis caused by Leishmania aethiopica: a systematic review","volume":"10","author":"van Griensven","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2021100522225270300_CIT0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tmi.12928","article-title":"Clinical features and treatment response of cutaneous leishmaniasis in north-west Ethiopia","volume":"22","author":"Fikre","year":"2017","journal-title":"Trop Med Int Health"},{"key":"2021100522225270300_CIT0021","first-page":"1","article-title":"Ocular leishmaniasis","volume":"19","author":"Modarreszadeh","year":"2006","journal-title":"Iran J Ophthalmol"},{"key":"2021100522225270300_CIT0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0049475519877317","article-title":"Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India","volume":"50","author":"Saurabh","year":"2020","journal-title":"Trop Doct"},{"key":"2021100522225270300_CIT0023","doi-asserted-by":"crossref","first-page":"e0006781","DOI":"10.1371\/journal.pntd.0006781","article-title":"Corneal complications following post kala-azar dermal leishmaniasis treatment","volume":"12","author":"Maruf","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2021100522225270300_CIT0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/ICO.0000000000001396","article-title":"Keratitis after post-kala-azar dermal leishmaniasis","volume":"37","author":"Pradhan","year":"2018","journal-title":"Cornea"},{"key":"2021100522225270300_CIT0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1517\/21678707.2015.1039510","article-title":"Miltefosine, an FDA-approved drug for the \u201corphan disease,\u201d leishmaniasis","volume":"3","author":"Berman","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"2021100522225270300_CIT0026","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine\u2014a life-saving drug for leishmaniasis\u2014is unavailable to people who need it the most","volume":"3","author":"Sunyoto","year":"2018","journal-title":"BMJ Glob Health"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1238\/34058602\/ciaa1238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e2457\/40511007\/ciaa1238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e2457\/40511007\/ciaa1238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T18:27:13Z","timestamp":1633717633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/7\/e2457\/5943554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,10,28]]},"published-print":{"date-parts":[[2021,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1238","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,10,28]]}}}